Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ustekinumab biosimilar by Rani Therapeutics for Psoriatic Arthritis: Likelihood of Approval
Ustekinumab biosimilar is under clinical development by Rani Therapeutics and currently in Phase I for Psoriatic Arthritis. According to GlobalData,...
Ustekinumab biosimilar by Rani Therapeutics for Psoriasis: Likelihood of Approval
Ustekinumab biosimilar is under clinical development by Rani Therapeutics and currently in Phase I for Psoriasis. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Rani Therapeutics's Ustekinumab Biosimilar?
Ustekinumab Biosimilar is a monoclonal antibody commercialized by Rani Therapeutics, with a leading Phase I program in Psoriatic Arthritis. According...